Day 1

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

solaci
solaci
394
0

Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month follow up scheme. No differences were observed in the composite cardio-renal end points, neither when CV and renal end points were observed individually.

Altitude-slides
Hans Henrik Parving
2012-08-25

Original title: ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints

Previous article
PURE: This study shows different patterns of cardiovascular risk factor prevalence in countries with different socio-economical background, and recommends individualized intervention..
Next article
PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .
solaci
solaci

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

solaci - 0
 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

solaci - 0
 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

solaci - 0
Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating...

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

solaci - 0
Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25
solaci -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

Dr. Omar Tupayachi - 0
The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

Dr. Omar Tupayachi - 0
As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...